Orforglipron is an oral GLP-1 receptor agonist being investigated for the treatment of early type 2 diabetes. The study evaluated 559 participants with a mean glycated hemoglobin (HbA1c) of 8.0% at baseline. After 40 weeks, patients treated with orforgliprone had a decrease in HbA1c of 1.24 percentage points at the 3 mg dose, 1.47 percentage points at the 12 mg dose, and 1.48 percentage points at the 36 mg dose. In the placebo group, the decrease in HbA1c was 0.41 percentage points. All doses of orforglipron were statistically significantly more effective compared to placebo. The most frequent adverse effects were gastrointestinal, mostly mild to moderate. The study confirmed that orforglipron significantly reduced HbA1c levels in patients with early type 2 diabetes.